Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Latest From Anju Ghangurde

US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?

The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market. 

Commercial Strategy

Dr Reddy’s Signals Reset In Europe

Dr Reddy’s enjoyed a strong showing in Europe in the fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. The firm’s China growth strategy is 'still valid', management maintains.

Strategy Sales & Earnings

Dr Reddy’s Signals Reset In Europe Business

Strong showing by Dr Reddy’s in Europe in fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. China growth strategy 'still valid', management maintains.

Commercial Sales & Earnings

India Pharma Webinar: COVID-19 Impact, Dealing With Business Continuity

Informa Markets’ recent webinar on COVID-19 and its impact on the Indian pharmaceutical industry deliberated a range of burning issues across the sector’s spectrum of activities, including efforts to stem India’s vulnerable dependency on active pharmaceutical ingredients imported from China, current trends for the excipients and pharma machinery segments and how industry is handling demand-supply disruptions in these challenging times.

India Coronavirus COVID-19

Cipla Propels 'Lung Leadership' Plans

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.

Strategy Sales & Earnings

COVID-19 Dents Biocon Ahead Of Insulin Opportunity

Biocon’s fourth-quarter earnings were impacted by pandemic-related disruptions, especially its biologics arm, but the Indian firm anticipates a “good recovery.” All eyes will be on the anticipated US launch of biosimilar insulin glargine and its interchangeability status, while the company remains confident of delivering a $1bn FY2022 revenue target for biologics.

Sales & Earnings Biosimilars
See All
UsernamePublicRestriction

Register